Apoptosis Inhibitors
- Technology Benefits
- Unique chemistry and stability under physiological conditions. Potent compounds active in nanomolar range with an IC50 several fold lower than other apoptosis inhibitors such as pifithrin. Demonstrated efficacy in animal models.
- Technology Application
- Wide range of clinical treatments where suppression of apoptosis of normal cells is desirable such as radiation and chemotherapy for human cancers to prevent side effects that include mucositis, hair loss, myelosuppression and diarrhea. Protection from apoptosis in heart and brain ischemia, peripheral limb protection in vascular disease and prevention of shock resulting from viral or bacterial infections, or burns.
- Detailed Technology Description
- Researchers at the University of California have developed novel heterocyclic compounds that protect normal cells from apoptosis. These compounds are active in vitro in the nanomolar range and prevent apoptosis in cells treated with glucocorticoids or ionizing radiation. In addition, the compounds also significantly increase survival rates of mice irradiated with gamma rays with no observable toxicity.
- Supplementary Information
- Patent Number: US6696441B1
Application Number: US2000637531A
Inventor: Cottam, Howard B. | Leoni, Lorenzo M. | Carson, Dennis A.
Priority Date: 11 Aug 2000
Priority Number: US6696441B1
Application Date: 11 Aug 2000
Publication Date: 24 Feb 2004
IPC Current: A61K0031519 | C07D048704 | C07D051304
US Class: 5142332 | 514322 | 514368 | 514375 | 544115 | 546199 | 5462704 | 5462731 | 5462741 | 548151 | 548218 | 548368
Assignee Applicant: The Regents of the University of California
Title: Inhibition of p53-induced stress response
Usefulness: Inhibition of p53-induced stress response
Summary: In the manufacture of medicament useful to prevent detrimental effect upon cells due to DNA damage such as caused by chemotherapy, radiation, ischemic event e.g. stroke, infarct, ischemia reperfusion injury and organ transplantation, environmental pollution or contamination, etc; for study of the physiological processes associated with intracellular DNA damage; to prevent growth of microorganisms; to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other cancer treatments.
Novelty: New polycyclic imidazole derivatives useful for preventing detrimental effects of e.g. stroke
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Others
-
State Of Development
Synthesized product was formulated as a topical ointment, which was efficacious, in vivo (mouse), for healing of irradiation-induced skin damage (see Related Materials).
Research interests can be found at: http://cancer.ucsd.edu/Research/summaries/dcarson.asp
Related Materials
Additional Technologies by these Inventors
Tech ID/UC Case
22359/2005-E50-0
Related Cases
2005-E50-0, 2000-E70-0
- *Abstract
-
Although treatment of cancer through non-surgical methods such as chemotherapy and radiation has dramatically improved survival rates, these therapies are associated with a fair degree of toxicity. The deleterious effects are particularly due to inability of these treatment methods to target cancer cells specifically without affecting surrounding normal cells. The challenge therefore, has been to find methods of selectively protecting normal cells, while maintaining susceptibility of cancer cells to therapy. Apoptosis triggered by chemotherapy and radiation is the most common cause of destruction of normal cells and is due to activation of a fully functional p53 protein present in these cells. p53 protein-induced transactivation of several genes involved in the apoptosis pathway leads to elimination of normal cells when exposed to anti-cancer agents. Therefore, therapeutic suppression of p53 directly or of its pathways leading to apoptosis, are attractive targets to prevent damage to normal cells during anti-cancer therapy. Earlier efforts in this area led to the isolation of a chemoprotectant, pifithrin that protected normal cells against radiation and chemotherapy-induced damage. However, this agent was not potent, was unstable and was not a specific inhibitor of p53-related apoptotic pathways. Hence, there is a clear need for new chemical inhibitors that are more robust, stable and specific as chemoprotectants of normal cells during anti-cancer therapy.
- *Principal Investigator
-
Name: Sylvie Barchechath
Department:
Name: Dennis Carson
Department:
Name: Mary Corr
Department:
Name: Howard Cottam
Department:
- Country/Region
- USA
